Vistagen Therapeutics (VTGN) Other financing activities (2018 - 2025)
Vistagen Therapeutics (VTGN) posted Other financing activities of -$154000.0 for Q4 2025, down 195.65% sequentially from $161000.0 in Q2 2025, and down 75.0% YoY from -$616000.0 in Q4 2024.
Vistagen Therapeutics (VTGN) Other financing activities (2018 - 2025) Analysis & Trends
Vistagen Therapeutics has reported Other financing activities for 7 years, with the latest figure at -$154000.0 in Q4 2025.
- Quarterly Other financing activities fell 75.0% year-over-year to -$154000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$81000.0 (down 2800.0% YoY) and the FY2023 annual result came in at $6.2 million, changed 0.0% from the prior year.
- Other financing activities retreated to -$154000.0 in Q4 2025 per VTGN's latest filing, from $161000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $4.9 million in Q1 2021 and troughed at -$154000.0 in Q4 2025.
- A 5-year average of $867269.2 and a median of $88000.0 in 2024 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 2100.0% in 2024, down 3033.33% in 2024.
- Over 5 years, Other financing activities stood at $2.0 million in 2021, then slumped by 99.77% to $4400.0 in 2022, then sank by 31.82% to $3000.0 in 2023, then tumbled by 3033.33% to -$88000.0 in 2024, then slumped by 75.0% to -$154000.0 in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered -$154000.0, $161000.0, and -$88000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -154,000.00 |
| Dec 31, 2025 | -154,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Dec 31, 2024 | -88,000.00 |
| Dec 31, 2024 | -88,000.00 |
| Jun 30, 2024 | 88,000.00 |
| Jun 30, 2024 | 88,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Sep 30, 2022 | 4,400.00 |
| Sep 30, 2022 | 4,400.00 |
| Jun 30, 2022 | 156,100.00 |
| Jun 30, 2022 | 156,100.00 |
| Mar 31, 2022 | -7,400.00 |
| Mar 31, 2022 | -7,400.00 |
| Dec 31, 2021 | 1.95 Mn |
| Dec 31, 2021 | 1.95 Mn |